- Home
- KLRS vs MGLD Comparison
KLRS vs MGLD Comparison
Compare KLRS & MGLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- MGLD
- Stock Information
- Founded
- KLRS 2019
- MGLD 1996
- Country
- KLRS United States
- MGLD United States
- Employees
- KLRS N/A
- MGLD N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- MGLD Finance/Investors Services
- Sector
- KLRS Health Care
- MGLD Finance
- Exchange
- KLRS Nasdaq
- MGLD Nasdaq
- Market Cap
- KLRS 46.0M
- MGLD 44.8M
- IPO Year
- KLRS N/A
- MGLD N/A
- Fundamental
- Price
- KLRS $6.31
- MGLD $1.02
- Analyst Decision
- KLRS Strong Buy
- MGLD
- Analyst Count
- KLRS 3
- MGLD 0
- Target Price
- KLRS $21.50
- MGLD N/A
- AVG Volume (30 Days)
- KLRS 147.9K
- MGLD 12.3K
- Earning Date
- KLRS 11-12-2025
- MGLD 11-07-2025
- Dividend Yield
- KLRS N/A
- MGLD N/A
- EPS Growth
- KLRS N/A
- MGLD N/A
- EPS
- KLRS N/A
- MGLD N/A
- Revenue
- KLRS N/A
- MGLD $29,207,000.00
- Revenue This Year
- KLRS N/A
- MGLD N/A
- Revenue Next Year
- KLRS N/A
- MGLD N/A
- P/E Ratio
- KLRS N/A
- MGLD N/A
- Revenue Growth
- KLRS N/A
- MGLD N/A
- 52 Week Low
- KLRS $2.14
- MGLD $0.64
- 52 Week High
- KLRS $12.90
- MGLD $2.10
- Technical
- Relative Strength Index (RSI)
- KLRS 57.79
- MGLD 50.12
- Support Level
- KLRS $6.04
- MGLD $0.90
- Resistance Level
- KLRS $7.07
- MGLD $1.11
- Average True Range (ATR)
- KLRS 0.66
- MGLD 0.07
- MACD
- KLRS 0.08
- MGLD 0.00
- Stochastic Oscillator
- KLRS 64.94
- MGLD 57.14
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About MGLD The Marygold Companies Inc.
The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.